Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Biological targeting nano-gene material and manufacturing method thereof

A nano-gene technology, applied in gene therapy, drug combination, pharmaceutical formula, etc., can solve the problems of non-targeting and inability to solve the problem of targeted treatment of lesions, and achieve the effect of less toxic and side effects

Inactive Publication Date: 2016-09-07
XIN HUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] In addition, in the current therapeutic products for cardiovascular diseases, the carrier used to load the gene is often not targeted during treatment, so it cannot solve the problem of targeted therapy in the case of enriched lesion sites

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Biological targeting nano-gene material and manufacturing method thereof
  • Biological targeting nano-gene material and manufacturing method thereof
  • Biological targeting nano-gene material and manufacturing method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0130] Embodiment 1, the synthesis of DGL-PEG

[0131] a) Weigh 22 mg (1 μmol) of DGL (MW: 25000) and dissolve it in 5 mL of PBS buffer (10 mM;

[0132] pH=7.4) (concentration 0.2 μmol / mL) (after weighing, place the solid DGL in a 10 mLep tube);

[0133] In this embodiment, DGL with other molecular weights can also be used, such as: MW=10000, 18000, 20000, 27000, 30000, 50000, 80000 or 100000.

[0134] b) Weigh 100 mg (50 μmol) of NHS-PEG2000-MAL (MW: 2000) and dissolve it in 5 mL of DMSO;

[0135] In this embodiment, NHS-PEG2000-MAL of other molecular weights can also be used, such as: MW=1000, 1800, 2100, 2700, 3000, 4500, 6500, 8000 or 10000.

[0136] In this example, during the scientific research on the reaction conditions, the reaction ratio between DGL and NHS-PEG2000-MAL was adjusted according to the different groups to be substituted. For example, the molar ratio of DGL and NHS-PEG2000-MAL is 1:2, 1:5, 1:10, 1:15, 1:25, 1:30, 1:40, 1:45, 1:50, 1:55, 1:60, 1:65, 1:6...

Embodiment 2

[0149] Embodiment two, the synthesis of DGL-PEG-AT1

[0150] The reaction equation is as follows:

[0151]

[0152] a) Weigh 22 mg (1 μmol) of DGL (MW: 25000) and dissolve it in 5 mL of PBS buffer (10 mM; pH=7.4) (concentration 0.2 μmol / mL) (after weighing, put the solid DGL in a 10 mLep tube);

[0153] In this embodiment, DGL with other molecular weights can also be used, such as: MW=10000, 18000, 20000, 27000, 30000, 50000, 80000 or 100000.

[0154] b) Weigh 100 mg (50 μmol) of NHS-PEG2000-MAL (MW: 2000) and dissolve it in 5 mL of DMSO;

[0155] In this embodiment, NHS-PEG2000-MAL of other molecular weights can also be used, such as: MW=1000, 1800, 2100, 2700, 3000, 4500, 6500, 8000 or 10000.

[0156] In this example, during the scientific research on the reaction conditions, the reaction ratio between DGL and NHS-PEG2000-MAL was adjusted according to the different groups to be substituted. For example, the molar ratio of DGL and NHS-PEG2000-MAL is 1:2, 1:5, 1:10, 1:15...

Embodiment 3

[0175] Embodiment 3, loaded antisense oligonucleotide

[0176] In this embodiment, AMO-1 is selected, and nanomaterials (NHS-PEG or NHS-PEG-MAL) and AMO-1 are loaded according to the mass ratio (20:1). Dissolve the nanomaterials and AMO-1 in DEPC water, add AMO-1 first into a 200 μL ep tube, then add the materials, mix by pipetting, vortex for 30 seconds, and incubate in a 47°C incubator for 1 hour. (Principle: electrostatic effect; DGL is positively charged, AMO-1 is negatively charged)

[0177] (Note 1: miRNA-1 increases in cardiomyocyte hypoxia, which promotes the apoptosis of cardiomyocytes and is a damage factor of cardiomyocytes. AMO-1 refers to the antisense oligonucleotide of miRNA-1, which is chemically synthesized The single-stranded RNA complementary to miRNA. It can complement the mature miRNA-1 in the cytoplasm, so that the damage effect of miRNA-1 is weakened.)

[0178] (Note 2: miRNA-1 sequence: 5'-UGGAAUGUAAAAGAAGUGUGUAU-3'

[0179] AMO-1 sequence: 5'-AUACAC...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a nano-gene material. The nano-gene material is characterized by comprising a targeting nano-gene substrate, the nano-gene substrate is prepared by amino acid polymer, modified polyethylene glycol and angiotensin II polypeptide, wherein the amino acid polymer and the angiotensin II polypeptide are chemically reacted with modified groups at two ends of the modified polyethylene glycol to produce the targeting nano-gene substrate. The novel nano-gene material provided has targeting to ischemic myocardium and protection for genes, excellent transfection effect and low toxicity.

Description

technical field [0001] The invention relates to the field of gene carriers, in particular to a bio-targeting nano-gene material and a manufacturing method thereof. Background technique [0002] In recent years, cardiovascular disease has become one of the diseases with the highest morbidity and mortality worldwide. Although gene therapy has achieved satisfactory results, safe and effective delivery vectors are still the bottleneck. Commonly used cardiac transport vectors can be divided into viral vectors and non-viral vectors. Due to the high transfection efficiency, the application of viral vectors still has an absolute advantage. However, due to the strong immune response caused by the virus vector, its clinical application is restricted. As an effective supplement to viral vectors, the research on non-viral vectors has been deepened in recent years. [0003] Non-viral vectors are non-infectious, have no carrier capacity limitation, have a wide range of material source...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K48/00A61P9/10A61P9/00
CPCA61K48/0041A61K48/005A61K31/7105
Inventor 何斌石学银薛晓梅董海青李永勇
Owner XIN HUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com